FOLH1 and posterior cortical atrophy: Compared with 177Lu-PSMA-617, 177Lu-EB-PSMA-617 accumulates significantly more in PSMA+ PCa tumors, reduces the needed dose of radioactivity 59, 60, is safe, and shows improved pharmacokinetics and therapeutic efficacy in 76 patients with progressive metastatic castration-resistant prostate cancer (mCRPC) 60-63.